Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have been given a consensus rating of “Moderate Buy” by the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $23.43.

Several research analysts have weighed in on TEVA shares. UBS Group decreased their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Friday. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Bank of America lowered their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. Finally, Barclays reduced their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Diversify Advisory Services LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 2.5% in the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock worth $426,000 after buying an additional 496 shares in the last quarter. Sanctuary Advisors LLC increased its holdings in Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock valued at $601,000 after acquiring an additional 664 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in Teva Pharmaceutical Industries by 0.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company’s stock worth $4,964,000 after purchasing an additional 699 shares in the last quarter. Townsquare Capital LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company’s stock valued at $885,000 after purchasing an additional 812 shares during the last quarter. Finally, Metis Global Partners LLC grew its position in shares of Teva Pharmaceutical Industries by 6.7% during the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company’s stock valued at $302,000 after purchasing an additional 860 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Trading Down 6.9 %

NYSE:TEVA opened at $13.83 on Friday. The company has a market cap of $15.68 billion, a PE ratio of -9.54, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The company has a 50 day simple moving average of $16.52 and a two-hundred day simple moving average of $18.01. Teva Pharmaceutical Industries has a 12 month low of $12.51 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Research analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.